Myriad Genetics' Upcoming Financial Release for Q1 2025
Myriad Genetics, Inc. (NASDAQ: MYGN), a prominent player in the field of molecular diagnostic testing and precision medicine, is set to unveil its first quarter financial results for 2025. The anticipated results will be disclosed on a significant date—May 6, when the market closes, followed by an earnings conference call at 4:30 pm EDT.
Engaging with Investors
During the call, Myriad's management will share an in-depth financial overview, along with a business update highlighting the company's performance. Investors and analysts are encouraged to tune in, as this call will provide valuable insights into the first quarter of 2025 and the strategic direction of the company.
Accessing the Conference Call
For those interested in participating, the conference call will be available live through Myriad's Investor Relations website. A simple registration will grant participants access to a dial-in number and unique PIN needed to join. After the event, there will also be an archived version of the webcast for those unable to attend.
Investor Interactions Scheduled for Q2 2025
In addition to the upcoming earnings call, Myriad plans to be active in the investor arena during the second quarter of 2025. Management has confirmed participation in several key investor healthcare conferences.
Scheduled Conferences
- BofA Securities 2025 Health Care Conference – Fireside chat scheduled for May 14 at 3:00 pm EDT.
- Goldman Sachs 46th Annual Global Healthcare Conference – Fireside chat on June 11 at 2:00 pm EDT.
Live and archived webcasts from these presentations will also be available on the same Investor Relations website.
The Role of Myriad Genetics in the Healthcare Sector
Myriad Genetics stands at the forefront of molecular diagnostic testing and precision medicine, committed to enhancing health outcomes internationally. Their offerings include a range of molecular tests designed to assess disease risk and guide treatment decisions in various medical fields. Such innovations not only improve patient care but also have the potential to reduce healthcare costs significantly.
Commitment to Innovation
By developing advanced tests that provide crucial information on disease progression, Myriad Genetics empowers healthcare providers and patients alike. Their technology is crucial across various medical specialties, allowing for tailored treatment plans that enhance patient outcomes.
Contact Information for Investors and Media
For those seeking further information or wishing to engage with the company, Myriad Genetics has designated contacts available for inquiries:
Investor Contact:
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact:
Kate Schraml
(224) 875-4493
PR@myriad.com
Frequently Asked Questions
When will Myriad Genetics release its Q1 2025 financial results?
Myriad Genetics will release its financial results on May 6, 2025, after market close.
How can I participate in Myriad's earnings call?
Investors can register through Myriad's Investor Relations website to receive the dial-in information for the earnings call.
What will be discussed during the earnings call?
The management team will provide a financial overview and business update regarding the company's performance during Q1 2025.
Is there a way to access a recording of the earnings call?
Yes, an archived version of the earnings call will be available on Myriad's Investor Relations website shortly after the event.
What investor conferences will Myriad Genetics participate in during Q2 2025?
Myriad plans to participate in the BofA Securities 2025 Health Care Conference and the Goldman Sachs 46th Annual Global Healthcare Conference.
